In AML secondary to MPNs, the most common mutation is JAK2 V617F, which accounts for 98% of polycythemia vera (PV) and 55–60% of essential thrombocythemia (ET) and myelofibrosis cases [32]. This evidence concerns the gene JAK2 and acquired polycythemia vera.